PDF(Pubmed)
Abstract：
UNASSIGNED: Anti-rods and rings (anti-RR) antibodies have recently been described as a cytoplasmic pattern in IIF-based screening of autoantibodies on HEp-2 cells and ICAP has named it as AC-23. It is most frequently related to drug-induced antibody generation. This study aimed to investigate the clinical significance of AC-23 positivity and its relevance to the diagnosis and/or follow-up of the associated diseases and/or drug use.
UNASSIGNED: A multicenter retrospective study was conducted among 10 hospitals from six different provinces in Türkiye from January 2017 to December 2021. The laboratory data and clinical information of 600 patients with positive anti-RR antibodies out of 547.558 HEp-2 IIF ANA samples were analyzed.
UNASSIGNED: The distribution of AC-23 positive patients by year indicated a steady increase between 2017-2021. Anti-RR prevalence in post-COVID-19 period was significantly higher than that of pre-COVID-19 period (p=0.00). Concomitant ANA positivity was detected in 56.5% of patients, the most common patterns being AC-4 and AC-5 (41.1%). The most frequent pathology among the anti-RR positive patients was an autoimmune disease (19.83%); 28.57% of which had rheumatoid arthritis and 17.65% autoimmune liver disease. Among the 600 patients, 65 (10.83%) were diagnosed as hepatitis C virus (HCV) infection. Available data for 38 of the HCV patients revealed that 71.05% of them had a history of interferon alfa+ribavirin and 28.95% of them had a history of NS3/4/5A/5B polymerase inhibitor or protease inhibitor drug use. Significant increase in the rate of anti-RR positivity was observed in the post-COVID-19 period when compared to pre-COVID-19 period (p:0.00).
UNASSIGNED: This is the first multicenter study in Türkiye about the clinical association of anti-RR antibodies which may be ignored during routine HEp-2 IIF testing. Pathologies other than HCV should be taken into consideration in terms of the possible role of anti-RR in autoimmune diseases and other pathologies. The preliminary data obtained in this study suggest that anti-RR antibody development might also be associated to COVID-19, supporting the several previous data related to the potential of viruses triggering the formation of autoantibodies. Large-scale prospective studies should elucidate the clinical significance of RR pattern and determine its role in patient diagnosis and follow-up.
UNASSIGNED: A multicenter retrospective study was conducted among 10 hospitals from six different provinces in Türkiye from January 2017 to December 2021. The laboratory data and clinical information of 600 patients with positive anti-RR antibodies out of 547.558 HEp-2 IIF ANA samples were analyzed.
UNASSIGNED: The distribution of AC-23 positive patients by year indicated a steady increase between 2017-2021. Anti-RR prevalence in post-COVID-19 period was significantly higher than that of pre-COVID-19 period (p=0.00). Concomitant ANA positivity was detected in 56.5% of patients, the most common patterns being AC-4 and AC-5 (41.1%). The most frequent pathology among the anti-RR positive patients was an autoimmune disease (19.83%); 28.57% of which had rheumatoid arthritis and 17.65% autoimmune liver disease. Among the 600 patients, 65 (10.83%) were diagnosed as hepatitis C virus (HCV) infection. Available data for 38 of the HCV patients revealed that 71.05% of them had a history of interferon alfa+ribavirin and 28.95% of them had a history of NS3/4/5A/5B polymerase inhibitor or protease inhibitor drug use. Significant increase in the rate of anti-RR positivity was observed in the post-COVID-19 period when compared to pre-COVID-19 period (p:0.00).
UNASSIGNED: This is the first multicenter study in Türkiye about the clinical association of anti-RR antibodies which may be ignored during routine HEp-2 IIF testing. Pathologies other than HCV should be taken into consideration in terms of the possible role of anti-RR in autoimmune diseases and other pathologies. The preliminary data obtained in this study suggest that anti-RR antibody development might also be associated to COVID-19, supporting the several previous data related to the potential of viruses triggering the formation of autoantibodies. Large-scale prospective studies should elucidate the clinical significance of RR pattern and determine its role in patient diagnosis and follow-up.
摘要：
抗杆和环(抗RR)抗体最近已被描述为HEp-2细胞上的自身抗体的基于IIF的筛选中的细胞质模式,并且ICAP将其命名为AC-23。最常见的是与药物诱导的抗体产生有关。本研究旨在探讨AC-23阳性的临床意义及其与相关疾病和/或药物使用的诊断和/或随访的相关性。
从2017年1月至2021年12月，对来自蒂尔基耶六个不同省份的10家医院进行了一项多中心回顾性研究。分析了547.558例HEp-2IIFANA样本中600例抗RR抗体阳性患者的实验室数据和临床信息。
■按年份划分的AC-23阳性患者的分布表明，2017-2021年之间呈稳定增长。COVID-19后时期的抗RR患病率显着高于COVID-19前时期（p=0.00）。在56.5%的患者中检测到合并ANA阳性，最常见的模式是AC-4和AC-5(41.1%)。抗RR阳性患者中最常见的病理是自身免疫性疾病（19.83％）；其中28.57％患有类风湿关节炎和17.65％的自身免疫性肝病。在600名患者中，65例(10.83%)被诊断为丙型肝炎病毒(HCV)感染。38名HCV患者的可用数据显示，其中71.05％有干扰素α+利巴韦林病史，其中28.95％有NS3/4/5A/5B聚合酶抑制剂或蛋白酶抑制剂药物使用史。与COVID-19前期相比，在COVID-19后期间观察到抗RR阳性率显着增加(p：0.00)。
■这是Türkiye关于抗RR抗体的临床关联的第一个多中心研究，在常规HEp-2IIF测试中可以忽略。在抗RR在自身免疫疾病和其他病理中的可能作用方面，应考虑HCV以外的病理。这项研究获得的初步数据表明，抗RR抗体的产生也可能与COVID-19有关，支持了先前与病毒引发自身抗体形成的潜力有关的几个数据。大规模前瞻性研究应阐明RR模式的临床意义，并确定其在患者诊断和随访中的作用。
从2017年1月至2021年12月，对来自蒂尔基耶六个不同省份的10家医院进行了一项多中心回顾性研究。分析了547.558例HEp-2IIFANA样本中600例抗RR抗体阳性患者的实验室数据和临床信息。
■按年份划分的AC-23阳性患者的分布表明，2017-2021年之间呈稳定增长。COVID-19后时期的抗RR患病率显着高于COVID-19前时期（p=0.00）。在56.5%的患者中检测到合并ANA阳性，最常见的模式是AC-4和AC-5(41.1%)。抗RR阳性患者中最常见的病理是自身免疫性疾病（19.83％）；其中28.57％患有类风湿关节炎和17.65％的自身免疫性肝病。在600名患者中，65例(10.83%)被诊断为丙型肝炎病毒(HCV)感染。38名HCV患者的可用数据显示，其中71.05％有干扰素α+利巴韦林病史，其中28.95％有NS3/4/5A/5B聚合酶抑制剂或蛋白酶抑制剂药物使用史。与COVID-19前期相比，在COVID-19后期间观察到抗RR阳性率显着增加(p：0.00)。
■这是Türkiye关于抗RR抗体的临床关联的第一个多中心研究，在常规HEp-2IIF测试中可以忽略。在抗RR在自身免疫疾病和其他病理中的可能作用方面，应考虑HCV以外的病理。这项研究获得的初步数据表明，抗RR抗体的产生也可能与COVID-19有关，支持了先前与病毒引发自身抗体形成的潜力有关的几个数据。大规模前瞻性研究应阐明RR模式的临床意义，并确定其在患者诊断和随访中的作用。
